Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Blank Check IPOs (SPACS) -- Ignore unavailable to you. Want to Upgrade?

To: Glenn Petersen who wrote (2323)	10/29/2010 8:22:22 AM
From: Glenn Petersen	Read Replies (1) \| Respond to of 3862

PharmAthene is taking advantage of the recent run-up in its stick price: PharmAthene Announces Pricing of $15 Million Public Offering Press Release Source: PharmAthene, Inc. On Friday October 29, 2010, 8:16 am ANNAPOLIS, Md., Oct. 29 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP) ("PharmAthene" or the "Company"), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that it has priced a registered public offering of 4,300,000 shares of its common stock at a price to the public of $3.50 per share. The Company expects that the offering will yield net proceeds, before expenses, of approximately $14.1 million and intends to use the net proceeds of the offering for repayment of debt and general corporate purposes. Roth Capital Partners, LLC served as sole underwriter for the offering. Noble Financial Capital Markets served as the Company's financial advisor in connection with the offering. In connection with the offering, the Company also granted the underwriter a 30-day option to purchase up to an additional 645,000 shares to cover over-allotments, if any. The offering is expected to close on or about November 3, 2010, subject to satisfaction of customary closing conditions. <snip> finance.yahoo.com